Cycl2R, just my two cents, I think a finance deal is even more prevalent since the risk is low for the financial institution with all the catalyst upcoming and the CYDY is not in the consumable items industry per say. With the huge market correction and the way the CV may effect many industries for the rest of 2020 potentially, the financing institution may want to deal with a BIO such as Cytodyn.